Adverse effects of oral glucocorticoid therapy - a brief review of literature
DOI:
https://doi.org/10.12775/JEHS.2025.78.57512Keywords
glucocorticoid therapy, side effects, excess glucocorticoids, adverse effectsAbstract
Introduction and Objective: Glucocorticoids (GCs) are among the most commonly prescribed pharmaceuticals across various medical specialties. The purpose of this article is to provide an overview of the most common side effects of oral glucocorticoid therapy and to underline the importance of educating healthcare professionals and patients on this topic.
State of knowledge: Glucocorticoids are commonly used in a wide range of patients because of their anti-inflammatory and immunosuppressive properties. Oral glucocorticoids can lead to a greater number of side effects in comparison with other routes of administration due to their systemic action. Adverse effects of glucocorticoid therapy involve endocrine, cardiovascular, musculoskeletal and central nervous systems. Patients often present with elevated serum glucose levels caused by reduced insulin sensitivity and amplified hepatic glucose production. Moreover, hyperglycemia and hypertension increase the risk of ischemic heart disease and heart failure. GCs impede bone formation and escalate bone resorption, resulting in bone mass reduction and osteoporosis. Myopathy may occur as a result of intensified catabolic processes. Glucocorticoid therapy impacts the production of cortisol by the adrenal glands and can lead to adrenal insufficiency and even adrenal crisis. Characteristic changes in external appearance aggravate self-esteem and mental health of patients resulting in decreased quality of life. Another adverse effect described in literature is substantial cognitive decline.
Summary: Despite their multiple positive applications, glucocorticoids are associated with numerous side effects. It is imperative for medical professionals to ascertain that the disadvantages do not outweigh the advantages of glucocorticoid therapy. Further research is needed to ensure that patients are provided with the best possible care.
References
[1] Kirwan JR, Balint G, Szebenyi B. Anniversary: 50 years of glucocorticoid treatment in rheumatoid arthritis. Rheumatology 1999;38:100–2. https://doi.org/10.1093/RHEUMATOLOGY/38.2.100.
[2] Wallace BI, Tsai HJ, Lin P, Aasbjerg K, Wu AC, Tsai YF, et al. Prevalence and prescribing patterns of oral corticosteroids in the United States, Taiwan, and Denmark, 2009–2018. Clin Transl Sci 2023;16:2565–76. https://doi.org/10.1111/CTS.13649.
[3] Fardet L, Petersen I, Nazareth I. Prevalence of long-term oral glucocorticoid prescriptions in the UK over the past 20 years. Rheumatology (Oxford) 2011;50:1982–90. https://doi.org/10.1093/RHEUMATOLOGY/KER017.
[4] Steroid-Corticosteroids - Market, Report Size, Worth, Revenue, Growth, Industry Value, Share 2024 n.d. https://reports.valuates.com/market-reports/QYRE-Auto-1C374/global-steroid-corticosteroids (accessed December 29, 2024).
[5] Waljee AK, Rogers MAM, Lin P, Singal AG, Stein JD, Marks RM, et al. Short term use of oral corticosteroids and related harms among adults in the United States: population based cohort study. The BMJ 2017;357:j1415. https://doi.org/10.1136/BMJ.J1415.
[6] Pofi R, Caratti G, Ray DW, Tomlinson JW. Treating the Side Effects of Exogenous Glucocorticoids; Can We Separate the Good From the Bad? Endocr Rev 2023;44:975. https://doi.org/10.1210/ENDREV/BNAD016.
[7] INGLE DJ, BEARY DF, PURMALIS A. Some further observations on steroid diabetes in the rat. Acta Endocrinol (Copenh) 1954;15:129–32. https://doi.org/10.1530/ACTA.0.0150129.
[8] Delfs N, Struja T, Gafner S, Muri T, Baechli C, Schuetz P, et al. Outcomes of Hospitalized Patients with Glucocorticoid-Induced Hyperglycemia—A Retrospective Analysis. J Clin Med 2020;9:4079. https://doi.org/10.3390/JCM9124079.
[9] Van Raalte DH, Diamant M. Steroid diabetes: from mechanism to treatment? Neth J Med. 2014 Feb;72(2):62-72. PMID: 24659588.
[10] Cho JH, Suh S. Glucocorticoid-Induced Hyperglycemia: A Neglected Problem. Endocrinology and Metabolism 2024;39:222. https://doi.org/10.3803/ENM.2024.1951.
[11] Blackburn D, Hux J, Mamdani M. Quantification of the Risk of Corticosteroid-induced Diabetes Mellitus Among the Elderly. J Gen Intern Med 2002;17:717. https://doi.org/10.1046/J.1525-1497.2002.10649.X.
[12] Nakamura H, Fujieda Y, Nakamura A, Atsumi T. How should rheumatologists manage glucocorticoid-induced hyperglycemia? Mod Rheumatol 2021;31:519–28. https://doi.org/10.1080/14397595.2020.1823060.
[13] Katsuyama T, Sada KE, Namba S, Watanabe H, Katsuyama E, Yamanari T, et al. Risk factors for the development of glucocorticoid-induced diabetes mellitus. Diabetes Res Clin Pract 2015;108:273–9. https://doi.org/10.1016/J.DIABRES.2015.02.010.
[14] Fardet L, Fève B. Systemic glucocorticoid therapy: A review of its metabolic and cardiovascular adverse events. Drugs 2014;74:1731–45. https://doi.org/10.1007/S40265-014-0282-9/METRICS.
[15] Ong SLH, Whitworth JA. How do glucocorticoids cause hypertension: role of nitric oxide deficiency, oxidative stress, and eicosanoids. Endocrinol Metab Clin North Am 2011;40:393–407. https://doi.org/10.1016/J.ECL.2011.01.010.
[16] Van Der Hooft CS, Heeringa J, Brusselle GG, Hofman A, Witteman JCM, Kingma JH, et al. Corticosteroids and the risk of atrial fibrillation. Arch Intern Med 2006;166:1016–20. https://doi.org/10.1001/ARCHINTE.166.9.1016.
[17] Wei L, MacDonald TM, Walker BR. Taking glucocorticoids by prescription is associated with subsequent cardiovascular disease. Ann Intern Med 2004;141. https://doi.org/10.7326/0003-4819-141-10-200411160-00007.
[18] Kuai J, Zheng J, Kumar A, Gao H. Anti-inflammatory, antiosteoporotic, and bone protective effect of hydroxysafflor yellow A against glucocorticoid-induced osteoporosis in rats. J Biochem Mol Toxicol 2024;38. https://doi.org/10.1002/JBT.23797.
[19] Gado M, Baschant U, Hofbauer LC, Henneicke H. Bad to the Bone: The Effects of Therapeutic Glucocorticoids on Osteoblasts and Osteocytes. Front Endocrinol (Lausanne) 2022;13:835720. https://doi.org/10.3389/FENDO.2022.835720/BIBTEX.
[20] Ziambaras K, Civitelli R. Epidemiology of glucocorticoid-induced osteoporosis. J Endocrinol Invest 2008;7:2–6. PMID: 18791344.
[21] Berris KK, Repp AL, Kleerekoper M. Glucocorticoid-induced osteoporosis. Curr Opin Endocrinol Diabetes Obes 2007;14:446–50. https://doi.org/10.1097/MED.0B013E3282F15407.
[22] Bodine SC, Furlow JD. Glucocorticoids and Skeletal Muscle. Adv Exp Med Biol 2015;872:145–76. https://doi.org/10.1007/978-1-4939-2895-8_7.
[23] Lee MK, Jeong HH, Kim MJ, Ryu HY, Baek JW, Lee BG. Nutrients against Glucocorticoid-Induced Muscle Atrophy. Foods 2022;11:687. https://doi.org/10.3390/FOODS11050687.
[24] Martin-Grace J, Dineen R, Sherlock M, Thompson CJ. Adrenal insufficiency: Physiology, clinical presentation and diagnostic challenges. Clin Chim Acta 2020;505:78–91. https://doi.org/10.1016/J.CCA.2020.01.029.
[25] Arlt W, Allolio B. Adrenal insufficiency. Lancet 2003;361:1881–93. https://doi.org/10.1016/S0140-6736(03)13492-7.
[26] Kesari S, Barron C, Cohen LE, Regelmann MO, Baer TG. Dexamethasone swish and spit: A cause of iatrogenic adrenal insufficiency. Pediatr Blood Cancer 2024;71:e31138. https://doi.org/10.1002/PBC.31138.
[27] Dinsen S, Baslund B, Klose M, Rasmussen AK, Friis-Hansen L, Hilsted L, et al. Why glucocorticoid withdrawal may sometimes be as dangerous as the treatment itself. Eur J Intern Med 2013;24:714–20. https://doi.org/10.1016/J.EJIM.2013.05.014.
[28] Broersen LHA, Pereira AM, Jørgensen JOL, Dekkers OM. Adrenal Insufficiency in Corticosteroids Use: Systematic Review and Meta-Analysis. J Clin Endocrinol Metab 2015;100:2171–80. https://doi.org/10.1210/JC.2015-1218.
[29] J. M. Schaaf M, Meijer OC. Immune Modulations by Glucocorticoids: From Molecular Biology to Clinical Research. Cells 2022, Vol 11, Page 4032 2022;11:4032. https://doi.org/10.3390/CELLS11244032.
[30] Chastain DB, Spradlin M, Ahmad H, Henao-Martínez AF. Unintended Consequences: Risk of Opportunistic Infections Associated With Long-term Glucocorticoid Therapies in Adults. Clinical Infectious Diseases 2024;78:e37–56. https://doi.org/10.1093/CID/CIAD474.
[31] Franco LM, Gadkari M, Howe KN, Sun J, Kardava L, Kumar P, et al. Immune regulation by glucocorticoids can be linked to cell type-dependent transcriptional responses. J Exp Med 2019;216:384–406. https://doi.org/10.1084/JEM.20180595.
[32] George MD, Baker JF, Winthrop K, Hsu JY, Wu Q, Chen L, et al. Risk for Serious Infection With Low-Dose Glucocorticoids in Patients With Rheumatoid Arthritis A Cohort Study. Ann Intern Med 2020;173:870. https://doi.org/10.7326/M20-1594.
[33] Wilson JC, Sarsour K, Gale S, Pethö-Schramm A, Jick SS, Meier CR. Incidence and Risk of Glucocorticoid-Associated Adverse Effects in Patients With Rheumatoid Arthritis. Arthritis Care Res (Hoboken) 2019;71:498–511. https://doi.org/10.1002/ACR.23611.
[34] Aljebab F, Choonara I, Conroy S. Systematic Review of the Toxicity of Long-Course Oral Corticosteroids in Children. PLoS One 2017;12:e0170259. https://doi.org/10.1371/JOURNAL.PONE.0170259.
[35] Newell-Price J, Bertagna X, Grossman AB, Nieman LK. Cushing’s syndrome. Lancet 2006;367:1605–17. https://doi.org/10.1016/S0140-6736(06)68699-6.
[36] Castinetti F, Morange I, Conte-Devolx B, Brue T. Cushing’s disease. Orphanet J Rare Dis 2012;7:41. https://doi.org/10.1186/1750-1172-7-41.
[37] Oray M, Abu Samra K, Ebrahimiadib N, Meese H, Foster CS. Long-term side effects of glucocorticoids. Expert Opin Drug Saf 2016;15:457–65. https://doi.org/10.1517/14740338.2016.1140743.
[38] Filaretova L, Podvigina T, Yarushkina N. Physiological and Pharmacological Effects of Glucocorticoids on the Gastrointestinal Tract. Curr Pharm Des 2020;26:2962–70. https://doi.org/10.2174/1381612826666200521142746.
[39] Wolfe D, Kanji S, Yazdi F, Barbeau P, Rice D, Beck A, et al. Drug induced pancreatitis: A systematic review of case reports to determine potential drug associations. PLoS One 2020;15:e0231883. https://doi.org/10.1371/JOURNAL.PONE.0231883.
[40] Pivonello R, Simeoli C, De Martino MC, Cozzolino A, De Leo M, Iacuaniello D, et al. Neuropsychiatric disorders in Cushing’s syndrome. Front Neurosci 2015;9. https://doi.org/10.3389/FNINS.2015.00129.
[41] Wolkowitz OM, Lupien SJ, Bigler ED. The “steroid dementia syndrome”: a possible model of human glucocorticoid neurotoxicity. Neurocase 2007;13:189–200. https://doi.org/10.1080/13554790701475468.
[42] De Alcubierre D, Ferrari D, Mauro G, Isidori AM, Tomlinson JW, Pofi R. Glucocorticoids and cognitive function: a walkthrough in endogenous and exogenous alterations. J Endocrinol Invest 2023;46:1961. https://doi.org/10.1007/S40618-023-02091-7.
[43] Zhao C, He L, Li L, Deng F, Zhang M, Wang C, et al. Prenatal glucocorticoids exposure and adverse cardiovascular effects in offspring. Front Endocrinol (Lausanne) 2024;15:1430334. https://doi.org/10.3389/FENDO.2024.1430334.
[44] Tegethoff M, Pryce C, Meinlschmidt G. Effects of Intrauterine Exposure to Synthetic Glucocorticoids on Fetal, Newborn, and Infant Hypothalamic-Pituitary-Adrenal Axis Function in Humans: A Systematic Review. Endocr Rev 2009;30:753–89. https://doi.org/10.1210/ER.2008-0014.
[45] Braun T, Challis JR, Newnham JP, Sloboda DM. Early-life glucocorticoid exposure: the hypothalamic-pituitary-adrenal axis, placental function, and long-term disease risk. Endocr Rev 2013;34:885–916. https://doi.org/10.1210/ER.2013-1012.
[46] Matthews SG, Owen D, Kalabis G, Banjanin S, Setiawan EB, Dunn EA, et al. Fetal Glucocorticoid Exposure and Hypothalamo‐Pituitary‐Adrenal (HPA) Function After Birth. Endocr Res 2004;30:827–36. https://doi.org/10.1081/ERC-200044091.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Marta Gruszka, Paulina Polańska, Maria Kubicka, Martyna Zakrocka, Jakub Fick
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Stats
Number of views and downloads: 70
Number of citations: 0
